Annogen is heading to ESGCT 2025!

Annogen is thrilled to announce our participation in the upcoming European Society of Gene and Cell Therapy (ESGCT) conference, taking place from October 7th to 10th in beautiful Seville, Spain! As a leading force in advanced therapy innovation, we are eager to connect with fellow researchers, collaborators, and potential partners, showcasing our cutting-edge promoter and expression locus discovery platform.

The ESGCT conference is a cornerstone event for the gene and cell therapy community, bringing together experts from academia, industry, and regulatory bodies to share the latest breakthroughs and foster new collaborations. It’s an invaluable opportunity to discuss the future of gene therapies, and we are excited to be a part of these crucial conversations.

At Annogen, we specialize in accelerating genetic therapy development through our advanced promoter discovery platform. This platform empowers researchers to identify and optimize promoters that are crucial for precise and effective gene expression, ultimately leading to more potent and targeted therapeutic solutions. We believe our technology is paving the way for the next generation of gene therapies, and we can’t wait to showcase its capabilities.

We invite you to schedule a meeting to learn more about how Annogen can support your research and development efforts. Our team will be on hand to discuss our platform, answer your questions, and explore potential collaborations.

We are also proud to be presenting three scientific posters at ESGCT 2025, highlighting recent advancements and exciting data from our research:

• A comprehensive mutagenesis on viral promoters for potential improvements of AAV yield and packaging – Presented by Tijn van Balen (P0093)
• This poster will delve into our strategies for optimizing AAV viral promoters, with the goal of enhancing gene therapy vector production efficiency.
• Identification and in vivo validation of a neuroinflammation-responsive promoter for CNS gene therapies – Presented by Dr. Alexey Pindyurin (P0346)
• Discover our groundbreaking work in identifying promoters that specifically respond to neuroinflammation, offering new avenues for targeted CNS gene therapies.
• Inducible and constitutive T-Cell specific promoters identified by SuRE screening – Presented by Dr. Daan Peric Hupkes (P0710)
• Learn about our robust SuRE screening approach for discovering both inducible and constitutive T-cell specific promoters, critical for developing (in vivo) CAR-T cell therapies and improving viral vector yield.

We are looking forward to engaging discussions, forging new connections, and contributing to the vibrant ESGCT community. If you’re attending the conference, please reach out to schedule a meeting with our team – we’d love to connect!

See you in Seville!